Mylan N.V. (NASDAQ: MYL) is a large market cap stock with a market cap of 22571.81. It is in the Drugs – Generic industry and sector Healthcare, with a current P/E of 26.38, a forward P/E of 7.16 and EPS of 1.57. At a stock price of 41.49 (1.59%) it has a dividend yield of *TBA.
EPS growth for the last five years have been 20.20%, more recently this last year it has grown by -31.50%. The next year growth is going to be about 16.82% and more long-term 13.26% after five years. EPS growth quarter over quarter is 2.80%. Sales growth for the past five years have been 11.60% and sales growth quarter over quarter is 8.00%.
For performance, Mylan N.V. the past week has seen a gain of 2.27%. For the last month performance for Mylan N.V. is -14.51%. While the last quarter is -7.90% and half year, -6.17%. Finally for the year, performance is -15.34%.
The 52-week high for Mylan N.V., is at -25.26%, and for the 52-week low it comes to a value of 10.38%. The 20-day simple moving average is -8.50% and -11.25% for the 200-day simple moving average.
Volatility for the week is at 2.38%, and for the month it is 3.15%. Mylan N.V., has a target price of 57.35.
In terms of debt, long term debt/equity is 1.24, and for total debt/equity Mylan N.V. has 1.31. The gross margin is 45.30%, while operating margin is 15.70%, the profit margin is 8.10%. The current ratio is 3.2 and the quick ratio is 2.6.
Insider ownership is at 0.50%, with instituitional ownership at 64.50%. Mylan N.V. has a payout ratio of 0.00%. With the total shares outstanding coming to 544.03. The shares float is 438.9, with the float short at 4.96%, with short ratio coming to 3.86.
In terms of returns, the return on assets see Mylan N.V., get 3.40%, with its returns on investment at 8.20%. Return on equity is 8.00%. So will the investors see the target price of 57.35, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.